Ultragenyx Pharmaceutical (NASDAQ:RARE) CFO Sells $98,202.51 in Stock

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) CFO Howard Horn sold 4,683 shares of the business’s stock in a transaction on Wednesday, April 1st. The shares were sold at an average price of $20.97, for a total value of $98,202.51. Following the completion of the transaction, the chief financial officer owned 80,351 shares of the company’s stock, valued at $1,684,960.47. This trade represents a 5.51% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Howard Horn also recently made the following trade(s):

• On Tuesday, March 3rd, Howard Horn sold 1,635 shares of Ultragenyx Pharmaceutical stock. The stock was sold at an average price of $22.40, for a total value of $36,624.00.
• On Monday, March 2nd, Howard Horn sold 8,409 shares of Ultragenyx Pharmaceutical stock. The stock was sold at an average price of $22.70, for a total value of $190,884.30.
• On Monday, February 2nd, Howard Horn sold 3,061 shares of Ultragenyx Pharmaceutical stock. The shares were sold at an average price of $23.56, for a total value of $72,117.16.

Ultragenyx Pharmaceutical Stock Performance

Ultragenyx Pharmaceutical stock opened at $22.45 on Friday. The stock has a fifty day moving average price of $22.20 and a 200 day moving average price of $27.75. Ultragenyx Pharmaceutical Inc. has a 52 week low of $18.29 and a 52 week high of $42.37. The firm has a market capitalization of $2.21 billion, a P/E ratio of -3.84 and a beta of 0.25.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last issued its quarterly earnings results on Thursday, February 12th. The biopharmaceutical company reported ($1.29) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.20) by ($0.09). The business had revenue of $207.28 million during the quarter, compared to analyst estimates of $199.60 million. Ultragenyx Pharmaceutical had a negative return on equity of 1,024.42% and a negative net margin of 85.54%.The firm’s quarterly revenue was up 25.5% on a year-over-year basis. During the same period in the previous year, the business posted ($1.39) earnings per share. As a group, equities analysts predict that Ultragenyx Pharmaceutical Inc. will post -5.18 EPS for the current year.

More Ultragenyx Pharmaceutical News

Here are the key news stories impacting Ultragenyx Pharmaceutical this week:

• Positive Sentiment: FDA accepts the BLA resubmission for UX111 (AAV gene therapy for Sanfilippo syndrome type A). Acceptance starts a formal FDA review clock and materially improves near‑term clarity on a high‑value gene‑therapy program, which can lift pipeline valuation and upside expectations if the review proceeds smoothly. Read More.
• Neutral Sentiment: CFO Howard Horn disclosed sale of 4,683 shares under a pre‑arranged Rule 10b5‑1 plan; he retains a large position. Because the sale was executed under a 10b5‑1 schedule and his holding remains substantial, markets typically treat this as routine liquidity rather than a signal of undisclosed company problems. Read More.
• Neutral Sentiment: Recent analyst target/coverage updates (mix of cuts and reiterations) keep consensus near a “Moderate Buy” but with wide dispersion in targets, leaving valuation opinion split among investors. (Coverage changes may moderate momentum but are not a single catalytic change.)
• Negative Sentiment: Multiple plaintiff law firms have issued lead‑plaintiff solicitations for a securities class action covering Aug 3, 2023–Dec 26, 2025, with an imminent April 6 deadline. The wave of notices signals an active litigation overhang that can pressure the stock via potential discovery, legal costs, management distraction and settlement risk until the matter is resolved or clarified. Representative notices: Rosen Law Firm and Berger Montague. Read More. Read More.

Institutional Trading of Ultragenyx Pharmaceutical

Institutional investors and hedge funds have recently bought and sold shares of the business. Assetmark Inc. lifted its position in Ultragenyx Pharmaceutical by 1,706.7% during the third quarter. Assetmark Inc. now owns 1,084 shares of the biopharmaceutical company’s stock valued at $33,000 after buying an additional 1,024 shares in the last quarter. Huntington National Bank increased its position in shares of Ultragenyx Pharmaceutical by 56.2% in the third quarter. Huntington National Bank now owns 1,092 shares of the biopharmaceutical company’s stock worth $33,000 after acquiring an additional 393 shares in the last quarter. Danske Bank A S purchased a new position in shares of Ultragenyx Pharmaceutical in the 3rd quarter valued at $39,000. Smartleaf Asset Management LLC lifted its holdings in shares of Ultragenyx Pharmaceutical by 205.4% during the 3rd quarter. Smartleaf Asset Management LLC now owns 1,738 shares of the biopharmaceutical company’s stock valued at $53,000 after acquiring an additional 1,169 shares in the last quarter. Finally, Covestor Ltd lifted its holdings in shares of Ultragenyx Pharmaceutical by 26.0% during the 3rd quarter. Covestor Ltd now owns 1,787 shares of the biopharmaceutical company’s stock valued at $54,000 after acquiring an additional 369 shares in the last quarter. Institutional investors and hedge funds own 97.67% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts recently commented on RARE shares. JPMorgan Chase & Co. dropped their price target on shares of Ultragenyx Pharmaceutical from $120.00 to $74.00 and set an “overweight” rating for the company in a research report on Thursday, March 12th. Bank of America decreased their price target on shares of Ultragenyx Pharmaceutical from $72.00 to $58.00 and set a “buy” rating on the stock in a report on Friday, January 2nd. Weiss Ratings reissued a “sell (e+)” rating on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, January 21st. HC Wainwright dropped their price objective on Ultragenyx Pharmaceutical from $60.00 to $50.00 and set a “buy” rating for the company in a report on Tuesday, February 17th. Finally, The Goldman Sachs Group lowered Ultragenyx Pharmaceutical from a “buy” rating to a “neutral” rating and cut their target price for the stock from $61.00 to $25.00 in a research report on Tuesday, March 24th. One research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $60.47.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.